The group said that pharmaceutical companies’ intellectual property protections won’t prevent COVID-19 treatments and prophylactics from being globally available. It also said that such protections expedite the development of new COVID-19 products and help companies better share their technology and information to increase manufacturing.
“Eliminating those protections would undermine the global response to the pandemic, including ongoing effort to tackle new variants, create confusion that could potentially undermine public confidence in vaccine safety, and create a barrier to information sharing,” PhRMA wrote. “Most importantly, eliminating protections would not speed up production.”
More articles on pharmacy:
Pfizer vaccine 95% effective against coronavirus variant found in Brazil, small study shows
Detroit mayor declines J&J vaccine shipment, but says ‘each vaccine is safe’
3 top trends for the pharmacy industry in 2021 from CVS Health report
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
